Medtimo Files Patent Infringement Complaint Against Allurion Technologies [Yahoo! Finance]
Allurion Technologies, Inc. (ALUR)
Company Research
Source: Yahoo! Finance
IRVINE, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medtimo Inc , a wholly owned subsidiary of Biorad Medisys Private Limited, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, today announced that it has filed a patent infringement complaint in the U.S. District Court of the District of Delaware against Allurion Technologies, Inc. Medtimo's complaint, filed with the full support and backing of its parent company, Biorad Medisys Private Limited, details how Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion's recent unsuccessful challenge of Medtimo's patent rights in the U.S. Patent and Trademark Office (USPTO). The complaint alleges that Allurion has infringed three key Medtimo patents, and is a refiling of a previous complaint filed in 2023, but with two additional patents that were awarded by the USPTO to Medtimo later in 2023 and 2024, affir
Show less
Read more
Impact Snapshot
Event Time:
ALUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALUR alerts
High impacting Allurion Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
ALUR
News
- Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 AdherenceBusiness Wire
- New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention AloneBusiness Wire
- Allurion Technologies (NYSE:ALUR) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.MarketBeat
- Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight LossBusiness Wire
- Allurion Technologies Inc (ALUR) Q3 2025 Earnings Call Highlights: Strategic Restructuring and ... [Yahoo! Finance]Yahoo! Finance
ALUR
Earnings
- 5/14/25 - Beat
ALUR
Sec Filings
- 12/5/25 - Form 4
- 12/2/25 - Form 144
- 11/26/25 - Form D
- ALUR's page on the SEC website